Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia

被引:331
作者
Novick, Diego [1 ,2 ]
Haro, Josep Maria [3 ]
Suarez, David [3 ]
Perez, Victor [4 ]
Dittmann, Ralf W. [5 ]
Haddad, Peter M. [6 ,7 ]
机构
[1] Eli Lilly & Co, Lilly Res Ctr, Erl Wood Manor, Windlesham GU20 6PH, Surrey, England
[2] Univ Autonoma Barcelona, Dept Psiquiatria, Barcelona, Spain
[3] Ctr Invest Biomed Salud Mental CIBERSAM, Fundacio St Joan de Deu, St Joan de Deu SSM, Barcelona, Spain
[4] Hosp Sta Creu & St Pau, Dept Psychiat, Barcelona CIBERSAM, Barcelona, Spain
[5] Heidelberg Univ, Cent Inst Mental Hlth Mannheim, Eli Lilly Endowed Chair Pediat Psychopharmacol, D-6900 Heidelberg, Germany
[6] Greater Manchester W Mental Hlth NHS Fdn Trust, Manchester, Lancs, England
[7] Univ Manchester, Manchester M13 9PL, Lancs, England
关键词
Patient adherence; Risk factors; Treatment outcome; RISK-FACTORS; SUBSTANCE-ABUSE; ADHERENCE; NONCOMPLIANCE; REHOSPITALIZATION; HOSPITALIZATION; REMISSION; OUTCOMES; SUICIDE; CARE;
D O I
10.1016/j.psychres.2009.05.004
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
To assess baseline predictors and consequences of antipsychotic adherence during the long-term treatment of schizophrenia outpatients, data were taken from the 3-year, prospective, observational, European Schizophrenia Outpatients Health Outcomes (SOHO) study, in which outpatients starting or changing antipsychotics were assessed every 6 months. Physician-rated adherence was dichotomized as adherence/non-adherence. Regression models tested for predictors of adherence during follow-up, and associations between adherence and outcome measures. Of the 6731 patients analysed, 71.2% were adherent and 28.8% were non-adherent over 3 years. The strongest predictor of adherence was adherence in the month before baseline assessment. Other baseline predictors of adherence included initial treatment for schizophrenia and greater social activities. Baseline predictors of non-adherence were alcohol dependence and substance abuse in the previous month, hospitalization in the previous 6 months, independent housing and the presence of hostility. Non-adherence was significantly associated with an increased risk of relapse, hospitalization and suicide attempts. In conclusion, non-adherence is common but can partly be predicted. This may allow strategies to improve adherence to be targeted to high-risk patients. Also, reversal of some risk factors may improve adherence. Non-adherence is associated with a range of poorer long-term outcomes, with clinical and economic implications. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:109 / 113
页数:5
相关论文
共 32 条
[1]   Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care [J].
Ascher-Svanum, H ;
Faries, DE ;
Zhu, BJ ;
Ernst, FR ;
Swartz, MS ;
Swanson, JW .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (03) :453-460
[2]   A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia [J].
Ascher-Svanum, Haya ;
Zhu, Baojin ;
Faries, Douglas ;
Lacro, Jonathan P. ;
Dolder, Christian R. .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (07) :1114-1123
[3]   Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone [J].
Basson, BR ;
Kinon, BJ ;
Taylor, CC ;
Szymanski, KA ;
Gilmore, JA ;
Tollefson, GD .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (04) :231-238
[4]  
Buchanan A., 1996, Maudsley Monograph, V37
[5]   Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; A prospective five year follow-up [J].
De Haan, L. ;
Van Amelsvoort, T. ;
Dingemans, P. ;
Linszen, D. .
PHARMACOPSYCHIATRY, 2007, 40 (06) :264-268
[6]  
Fleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P10
[7]  
Guy W., 1976, CGI clinical global impressions
[8]   The Clinical Global Impression-Schizophrenia scale:: a simple instrument to measure the diversity of symptoms present in schizophrenia [J].
Haro, JM ;
Kamath, SA ;
Ochoa, S ;
Novick, D ;
Rele, K ;
Fargas, A ;
Rodríguez, MJ ;
Rele, R ;
Orta, J ;
Kharbeng, A ;
Araya, S ;
Gervin, M ;
Alonso, J ;
Mavreas, V ;
Lavrentzou, E ;
Liontos, N ;
Gregor, K ;
Jones, PB .
ACTA PSYCHIATRICA SCANDINAVICA, 2003, 107 :16-23
[9]   The European Schizophrenia Outpatient Health Outcomes (SOHO) study: Rationale, methods and recruitment [J].
Haro, JM ;
Edgell, ET ;
Jones, PB ;
Alonso, J ;
Gavart, S ;
Gregor, KJ ;
Wright, P ;
Knapp, M .
ACTA PSYCHIATRICA SCANDINAVICA, 2003, 107 (03) :222-232
[10]   Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results [J].
Haro, Josep Maria ;
Suarez, David ;
Novick, Diego ;
Brown, Jacqueline ;
Usall, Judith ;
Naber, Dieter .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 (04) :235-244